La Madeleine, France, and Thousand Oaks, CA, USA - May 23, 2023 – Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Beren is a vertically integrated biopharmaceutical company focused on addressing the world’s most significant health challenges. Roquette recognizes the revolutionary potential of Beren’s research to transform the market and the lives of millions of patients worldwide.
“Our refusal to stand still has helped us establish a leading market position and identify where the next big development in the pharma space is likely to emerge – and that’s what we see in our new relationship with Beren Therapeutics,” comments Paul Smaltz, Vice President of Pharmaceutical Solutions at Roquette. “We've been impressed by Beren's work as a Public Benefit Corporation and their innovations in manufacturing and drug development. Beren’s research indicates incredible untapped horizons in the cyclodextrin market that enable tackling the world’s greatest health challenges. This relationship can open up expanded capabilities for us in chemistry, manufacturing, controls (CMC) management, advancing safety protocols and regulatory registration.”
“Teaming up with Roquette is another step forward in our efforts to work across our ecosystem to accelerate ‘access for all," said Frank Langston, Beren’s Senior Vice President of Business Strategy. “We’re showcasing how outside-the-box collaboration can lead to greater societal impact and allow us to rapidly explore the untapped potential of our technology beyond our core business.”
“Working with Roquette is a natural fit. Bringing our teams closer together can only lead to faster innovation and opportunities that wouldn’t exist if we weren’t looking to engage outside our traditional domains,” said Jason Camm, CEO of Beren Therapeutics, P.B.C. “Both our missions align around pushing the boundaries of scientific innovation to benefit humanity, particularly when it comes to efficient and sustainable manufacturing processes.”
For more information on this announcement, please reach out to the contacts below.
To learn more about Roquette’s latest strategic partnerships and its wider cyclodextrins portfolio, visit our website.
About Beren Therapeutics, P.B.C.: Beren Therapeutics, P.B.C. is currently in stealth. Previous press releases: Beren Awarded Expedited Roadmap for Treatment of Homozygous Familial Hypercholesterolemia | Business Wire.
Beren Patient and Community Engagement - Cathy Traz - [email protected]
Roquette Global Pharmaceutical Business Communication - Emily Delommez - [email protected]
BDB Agency - [email protected] - +44 161 925 4700